Avita treats more US patients with Recell

Company News

by David Chau

The US Food and Drug Administration has made a decision which is beneficial to medical technology company, Avita Medical Ltd (ASX:AVH).

The FDA has increased the number of patients who can be treated for burns, cosmetic and reconstructive procedures – using Avita’s ReCell regenerative medical device. However, use of Recell is only allowed under special compassionate use protocols.

Avita says this protocol is triggered when the patient’s treating doctor believes there are no suitable alternative treatments.

This decision allows the company to treat up to 48 patients who don’t have enough healthy skin to undergo standard skin grafts. The company says, so far, there have been 34 compassionate cases in which patients were treated using ReCell.

Avita posted a net loss of $8.8 million at 30 June 2016.
 

David Chau

Finance News Network
David joined FNN in April 2016. In addition to presenting the Market Outlook and latest business news stories, David interviews senior economists and CEOs of ASX-listed companies. Prior to working for FNN, David was a litigation lawyer.